http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2540867-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67dd1f39f37bac4617e37d6d5c60aa8b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2011-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48c4c6b888a5235ac0dacf03a6289cb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c91d10a20f937ed36055691d22ff335f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c5c54fa8aa91a3b4b054455adf8d194 |
| publicationDate | 2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2540867-T3 |
| titleOfInvention | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors |
| abstract | A compound represented by the formula [I]: ** Formula ** in which: R 1 is hydrogen, halogen, C 1-6 alkyl or cyano; Ring A is an optionally substituted heterocyclic group, in which the heterocyclic moiety in the "optionally substituted heterocyclic group" represented by Ring A is monocyclic or bicyclic heteroaryl containing 1 to 3 nitrogen atoms as heteroatom or a group having a 5 to 6-membered aliphatic ring fused to it, and in which the "optionally substituted heterocyclic group" represented by ring A is a heterocyclic group optionally substituted with 1 to 6 substituent (s) that are the same or different and selected from the group consisting of C1-6 alkyl; C3-8 cycloalkyl; halogen; halo-C1-5 alkyl; hydroxy; C1-6 alkoxy; C1-5 haloalkoxy; amino optionally substituted with 1 to 2 substituent (s) that are the same or different and selected from C1-6 alkyl and halogen; and cyclic amino optionally substituted with 1 to 3 substituents (s) that are the same or different and selected from C1-6 alkyl and halogen; Ring B is an optionally substituted 3 to 6-membered monocyclic group, in which the unicycle moiety in the "optionally substituted 3 to 6-membered monocyclic group" represented by Ring B is a 4-monocyclic nitrogen-containing heterocyclic group. to 6 members or 3 to 6 member monocyclic hydrocarbon group, and wherein the "optionally substituted 3 to 6 member monocyclic group" represented by ring B is a 3 to 6 member monocyclic group optionally substituted with 1 to 3 substituent (s) that are the same or different and selected from the group consisting of halogen; oxo; hydroxy; C1-6 alkyl optionally substituted with 1 to 2 substituent (s) that are the same or different and selected from hydroxy and C1-6 alkoxy; C1-6 alkoxy; C1-6 alkyl sulfonyloxy; and amino optionally substituted with 1 to 2 substituent (s) that are the same or different and selected from C1-6 alkyl; and Y is represented by the formula [III]: -Z-R2 [III] in which Z is -N (R3) -, -O- or C1-2 alkylene; R3 is hydrogen; C1-6 alkyl optionally substituted with 1 to 2 substituent (s) that are the same or different and selected from hydroxy and C1-6 alkoxy; or C3-8 cycloalkyl; and R2 is (1) C1-6 alkyl optionally substituted with 1 to 3 substituent (s) that are the same or different and selected from the group consisting of hydroxy, halogen, cyano, C1-6 alkoxy, C3-8 cycloalkyl, C3 cycloalkyl -8 substituted with hydroxy, halo-C 1-5 alkyl and mono- or di-C 1-6 alkyl amino; or (2) an optionally substituted aliphatic 3- to 6-membered monocyclic group; wherein the unicycle moiety in the "optionally substituted 3 to 6 aliphatic monocyclic group" represented by R2 is selected from the group consisting of a 4 to 6 membered aliphatic monocyclic heterocyclic group containing 1 to 2 selected heteroatom (s) of oxygen atom, nitrogen atom and sulfur atom; and C3-6 cycloalkyl, and wherein the "optionally substituted aliphatic 3 to 6 membered monocyclic group" represented by R2 is an aliphatic 3 to 6 membered monocyclic group optionally substituted with 1 to 3 substituent (s) which are the same or different and selected from the group consisting of halogen; oxo; hydroxy; C2-7 alkanoyl; C1-6 alkoxy; and C1-6 alkyl optionally substituted with 1 to 2 substituent (s) that are the same or different and selected from hydroxy and C1-6 alkoxy; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2010-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 881.